Broderick Brian C Sells 175 Shares of Novo Nordisk A/S (NYSE:NVO)

Broderick Brian C decreased its holdings in Novo Nordisk A/S (NYSE:NVO) by 2.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,916 shares of the company’s stock after selling 175 shares during the quarter. Broderick Brian C’s holdings in Novo Nordisk A/S were worth $509,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Charles Schwab Investment Management Inc. lifted its position in Novo Nordisk A/S by 16.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 204,583 shares of the company’s stock worth $24,360,000 after buying an additional 28,988 shares in the last quarter. Benjamin Edwards Inc. lifted its position in shares of Novo Nordisk A/S by 643.8% during the third quarter. Benjamin Edwards Inc. now owns 25,697 shares of the company’s stock worth $3,060,000 after purchasing an additional 22,242 shares in the last quarter. Hilltop Holdings Inc. lifted its position in shares of Novo Nordisk A/S by 103.3% during the third quarter. Hilltop Holdings Inc. now owns 7,978 shares of the company’s stock worth $950,000 after purchasing an additional 4,054 shares in the last quarter. Integrated Wealth Concepts LLC increased its holdings in shares of Novo Nordisk A/S by 1.5% in the third quarter. Integrated Wealth Concepts LLC now owns 33,027 shares of the company’s stock valued at $3,933,000 after purchasing an additional 477 shares in the last quarter. Finally, IHT Wealth Management LLC raised its position in Novo Nordisk A/S by 39.9% in the 3rd quarter. IHT Wealth Management LLC now owns 11,311 shares of the company’s stock worth $1,343,000 after purchasing an additional 3,228 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on NVO shares. Kepler Capital Markets upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, March 13th. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Stifel Nicolaus lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Finally, StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Friday, March 21st. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $145.25.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $67.08 on Friday. Novo Nordisk A/S has a 12 month low of $63.67 and a 12 month high of $148.15. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $301.04 billion, a PE ratio of 20.39, a PEG ratio of 0.90 and a beta of 0.42. The stock’s fifty day simple moving average is $81.36 and its 200 day simple moving average is $97.26.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be given a dividend of $0.7874 per share. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio is currently 47.72%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.